With a $250,000 award from the Pancreatic Cancer Action Network, researchers will seek to validate biomarkers able to detect pancreas cancer months or years before patients experience overt symptoms of the disease. Pancreatic ductal adenocarcinoma is the deadliest of the major cancer types, with a five-year survival rate of less than 10 percent. Unlike the other major causes of cancer mortality, pancreatic cancer is increasing in both incidence and number of deaths each year. Principal investigator Brett Sheppard, … Read More
Posts Tagged ‘early detection’
OHSU Knight Cancer Institute Director Brian Druker talks with Medscape about breaking out of one-size-fits-all thinking in cancer screening and prevention ____________________ “We are now in the process of building an entire program on what I call precision early detection of cancer,” said Brian Druker, M.D., “We are trying to be more accurate in taking the same precepts of precision medicine for advanced cancer and using them earlier.” If it works, Druker told Medscape’s editor-in-chief, … Read More
“Oncologists actually are now optimists. When I started out in this business we were a bunch of pessimists,” Druker told a crowd at Portland’s Alberta Rose Theatre. “We’re seeing results we never thought imaginable.” For a taping of Live Wire Radio, OHSU Knight Cancer Institute Director Brian Druker, M.D., shared the stage with the indie rock band Blind Pilot, comedian Phoebe Robinson, and Bill Oakley, a writer for “The Simpsons.”
The inaugural Sondland-Durant Early Detection of Cancer Conference featured an appearance by comedian and television host Jay Leno. He led a discussion with Brian Druker, M.D., director of the OHSU Knight Cancer Institute, Sir Harpal Kumar, chief executive officer of Cancer Research UK, and Sanjiv Gambhir, M.D., Ph.D., a professor at Stanford University School of Medicine.
Nearly a century ago, a Greek immigrant physician in New York City began refining microscopy techniques for examining cells gently scraped from the female reproductive tract. The results were profound. George Papanicolaou’s Pap smear test gave the world a minimally invasive means to screen healthy women to reveal abnormally growing cervical cells that could be removed before any turned cancerous. And with it came the realization that cancer truly might be defeated by early detection.1
Immunovia’s “IMMray” technology uses an antibody microarray to detect the protein signature of pancreatic cancer in blood samples. The Swedish biotech firm Immunovia reached another milestone with the OHSU Knight Cancer Institute in developing a blood test to speed the diagnosis of pancreatic cancer. Immunovia’s antibody microarray correctly classified 96 percent of patients with stage I or II pancreatic ductal adenocarcinoma in a retrospective study using samples from North American pancreatic cancer patients. These results match … Read More
Sadik Esener, Ph.D., the engineer tapped to lead a major new cancer early detection program at the OHSU Knight Cancer Institute. Medical science has come up with only a few ways to detect incipient cancers in healthy people. None of them can distinguish the aggressive, life-threatening cases from those that are unlikely to become lethal. Researchers have spent decades, for instance, trying to develop a screening test for ovarian cancer. Most women with this … Read More
With the advent of mass screening by Pap smear, cervical cancer incidence and death rates declined by more than 60 percent in the U.S. between 1955 and 1992. It was a triumphant demonstration of the value of early detection. But the model has never worked so well for other common cancers. Mammography, for example, fails to detect one in four tumors in younger women while also delivering many false-positive results. Less than 5 percent of positive … Read More
Less than one in ten cases of pancreatic cancer in the U.S. are diagnosed at the local stage. And the relative survival rate — around 6 percent at five years — is by far the worst among major cancers. The OHSU Knight Cancer Institute and the Swedish biotech firm Immunovia AG recently announced a collaboration to develop blood tests that could enable earlier diagnosis of pancreatic cancer.
A preclinical study led by an OHSU Knight Cancer Institute physician may point the way to more effective tests for recurrence of acute myeloid leukemia. Nearly half of patients diagnosed with AML will eventually experience a relapse, even with the best available treatment. And those patients must undergo bone marrow biopsies to detect relapses, says Peter Kurre, M.D., who specializes in pediatric hematology/oncology and blood disorders. Bone marrow biopsies are uncomfortable for the patient … Read More